WASHINGTON — Pfizer may have been the first company to deliver on the promises of former President Trump’s Operation Warp Speed, but it was an exceedingly rocky road for the drugmaking giant and the administration’s team, according to a sweeping new book from a former official.
“Of all the companies in which we invested, Pfizer was both the least transparent and least collaborative,” writes Paul Mango, the federal health department’s deputy chief of staff under Trump.
Pfizer’s relationship with Trump was publicly contentious even when he was president — he even infamously accused the drugmaker of waiting to announce how well its vaccine worked until after the 2020 election. But Mango’s book reveals the extent of animosity and bickering that occurred between the two even as both pressed to respond to the Covid-19 pandemic.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
